While Low Affordability of HBV Therapies Is a Hurdle for Drug Marketers, an Affluent Upper Class Will Drive Use of Higher Priced Therapies, According to a New Report from Decision Resources
BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the hepatitis B virus (HBV) market in China will grow from $601 million in 2010 to nearly $900 million in 2015. According to the Emerging Markets report, Hepatitis B Virus in China, despite an increase in the drug-treated patient population that will expand the HBV market in China, low affordability of HBV therapies will limit its growth.
Low affordability of HBV therapies hinders both treatment rates and compliance. For example, the total cost of two-year therapy with GlaxoSmithKline’s Heptodin is about 1.4 times that of a rural Chinese resident’s income and 41 percent of an urban resident’s income. Meanwhile, the total course of peg-IFN-2a therapy is about 6.7 times that of a rural Chinese resident’s income and two times that of an urban resident’s income.
“In urban areas, high copayments and out-of-pocket expenses severely undermine patient compliance,” said Decision Resources Analyst Jing Wu, M.S., M.B.A. “In rural areas, although insurance coverage continues to expand to include reimbursement of more available HBV therapies, increasing HBV patient access to basic treatments, it probably will not provide the extent of drug cost reimbursement needed to expand the overall HBV therapeutic market in these areas.”
Despite these hurdles, the report notes that opportunities for Western HBV drug brands do exist as the emergence of the affluent middle and upper classes, who have greater spending power, will drive the desire for more-efficacious but higher-priced Western medicines.
“Chinese physicians and patients prefer branded Western medicines to domestically manufactured products, but to be competitive, Western pharmaceutical manufacturers must price their drugs competitively compared to the Chinese formulations of their products,” added Ms. Wu.
The new report features extensive primary research with Chinese gastroenterologists, hepatologists and infectious disease specialists as well as a market outlook through 2015.
About Emerging Markets Reports
Decision Resources is the first and only company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians’ practices.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
发表于 2011-6-13 23:43